<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6925523/results/search/disease/results.xml">
  <result pre="2019This is an open access article published by Portland Press" exact="Limited" post="on behalf of the Biochemical Society and distributed under"/>
  <result pre="be efficiently managed; however, the success of many drugs is" exact="limited" post="due to both patient non-compliance and adverse off-target or"/>
  <result pre="assessed in cancer, the immune system and neurodegenerative disorders including" exact="Parkinson's disease." post="Here, we review the effects that pharmacological agents have"/>
  <result pre="function and explore the opportunities from these effects as potential" exact="disease" post="treatments. Our focus will be on cancer treatment and"/>
  <result pre="effects as potential disease treatments. Our focus will be on" exact="cancer" post="treatment and immune modulation. Introduction Mitochondria are intracellular membrane-bound"/>
  <result pre="to maintain mitochondrial function at the synapse potentially leads to" exact="neuronal" post="dysfunction and neurodegeneration [10] with a disruption in mitochondrial"/>
  <result pre="at synaptic/neuromuscular junctions associated with motor neurone diseases such as" exact="amyotrophic lateral sclerosis" post="and Huntingdon's disease [11,12]. A diverse range of mitochondrial"/>
  <result pre="synaptic/neuromuscular junctions associated with motor neurone diseases such as amyotrophic" exact="lateral sclerosis" post="and Huntingdon's disease [11,12]. A diverse range of mitochondrial"/>
  <result pre="motor neurone diseases such as amyotrophic lateral sclerosis and Huntingdon's" exact="disease" post="[11,12]. A diverse range of mitochondrial functions have been"/>
  <result pre="beneficial and detrimental immune responses during pathogen infection, inflammatory diseases," exact="cancer" post="and aging [16–18]. This pivotal role in cell biology"/>
  <result pre="to enhance removal or turnover of damaged mitochondria associated with" exact="disease" post="or aging [21–24]. Toxic effects of pharmacological agents on"/>
  <result pre="life expectancy increases, long-term side effects of treatments have emerged." exact="Mitochondrial" post="dysfunction can result from different drug types through a"/>
  <result pre="major cornerstone in reducing the morbidity and mortality of various" exact="viral" post="infections such as human immunodeficiency virus (HIV). However, there"/>
  <result pre="cornerstone in reducing the morbidity and mortality of various viral" exact="infections" post="such as human immunodeficiency virus (HIV). However, there is"/>
  <result pre="morbidity and mortality of various viral infections such as human" exact="immunodeficiency" post="virus (HIV). However, there is a risk of NRTI-induced"/>
  <result pre="human DNA polymerases due to structural conservation between human and" exact="viral" post="polymerases and the disruption of dNTP pools [25]. Polymerase"/>
  <result pre="[28]. The clinical development of new antiviral agents to treat" exact="viral infection" post="produced compounds such as tenofovir, which has minimal mitochondrial"/>
  <result pre="The clinical development of new antiviral agents to treat viral" exact="infection" post="produced compounds such as tenofovir, which has minimal mitochondrial"/>
  <result pre="and lamivudine in modern HIV therapy, all of which report" exact="lower" post="mitochondrial toxicity than previous NRTIs [30]. Table 1. Summary"/>
  <result pre="of drugs with associated mitochondrial toxicity. Drug type Examples Mechanism" exact="Mitochondrial" post="effects Clinical symptoms Antiviral-nuceloside reverse transcriptase inhibitor (NRTI) Zidovudine"/>
  <result pre="lipid metabolism and altered carbohydrate metabolism [26]Red-ragged fibers in muscle," exact="myopathy" post="[138,139]Neuropathy, liver steacidosis, pancreatitis [29] Antiviral-protease inhibitor (PI) Saquinavir"/>
  <result pre="carbohydrate metabolism [26]Red-ragged fibers in muscle, myopathy [138,139]Neuropathy, liver steacidosis," exact="pancreatitis" post="[29] Antiviral-protease inhibitor (PI) Saquinavir (black box warning) Inhibits"/>
  <result pre="[146]Suppression of ETC complexes I and II [147] Tendinopathies, neuropathies," exact="myopathy" post="and psychological symptoms [143] Chemotherapy agent Cisplatin (black box"/>
  <result pre="DNA, inhibition of cell division and apoptotic cell death [148,149]" exact="Increased" post="ROS production [36,129]mtDNA damage in lung and prostate cancer"/>
  <result pre="death [148,149] Increased ROS production [36,129]mtDNA damage in lung and" exact="prostate cancer" post="cells [150]Decreased exercise capacity, decreased maximum mitochondrial ATP production"/>
  <result pre="[148,149] Increased ROS production [36,129]mtDNA damage in lung and prostate" exact="cancer" post="cells [150]Decreased exercise capacity, decreased maximum mitochondrial ATP production"/>
  <result pre="capacity, decreased maximum mitochondrial ATP production [151] Nephrotoxicity, ototoxicity [152]Peripheral" exact="neuropathy" post="[129]Cardiac myopathy [36]Hepatotoxicity [78] Anti-psychotic Clozapine (black box warning)"/>
  <result pre="maximum mitochondrial ATP production [151] Nephrotoxicity, ototoxicity [152]Peripheral neuropathy [129]Cardiac" exact="myopathy" post="[36]Hepatotoxicity [78] Anti-psychotic Clozapine (black box warning) Binds serotonin"/>
  <result pre="serotonin and dopamine receptors with off-target effects on mitochondria [153]" exact="Mitochondrial" post="membrane depolarization, increased inflammatory response, mitochondrial swelling and changes"/>
  <result pre="dehydrogenase and pyruvate kinase [50,154] Obesity, metabolic disturbances and increased" exact="diabetes" post="risk [50,154]Tardive dyskinesia [155] Antiepileptic Sodium valporate (black box"/>
  <result pre="of free acetyls CoA [157] Hepatotoxicity [51,52,157]Metabolic disturbances [52]Foetal anticonvulsant" exact="syndrome" post="[53] Antidepressant-selective serotonin reuptake inhibitor (SSRI) SertralineFluoxetine (black box"/>
  <result pre="and liver mitochondria [159,160]Reduced mitochondrial biogenesis [161]Ion compartmentalization [162]Change in" exact="morphology" post="to more rounded and shrivelled, indicative of increased caspase"/>
  <result pre="rounded and shrivelled, indicative of increased caspase 3 activity [163]Decreased" exact="respiratory" post="activity [164]Inhibition of complexes I, III and IV in"/>
  <result pre="ETC [163]Down-regulation of ETC proteins [165] Hyponatremia, weight gain [166]" exact="Mitochondrial" post="toxicity is also associated with other drug classes with"/>
  <result pre="responses being significantly influenced by patient–patient variability in mitochondrial function." exact="Mitochondrial" post="toxicity is also associated with other drug classes, with"/>
  <result pre="are acutely sensitive to aminoglycoside antibiotics, which can result in" exact="deafness" post="[31]. Age-related deafness (presbyacusis) is extremely common in western"/>
  <result pre="to aminoglycoside antibiotics, which can result in deafness [31]. Age-related" exact="deafness" post="(presbyacusis) is extremely common in western societies affecting half"/>
  <result pre="impact on mitochondrial function by many common medications on age-related" exact="deafness" post="cannot be ruled out [32]. Since the 1920s, cardiovascular"/>
  <result pre="age-related deafness cannot be ruled out [32]. Since the 1920s," exact="cardiovascular" post="diseases have been the leading cause of death globally"/>
  <result pre="leading cause of death globally (World Health Organization). Statins which" exact="lower" post="lipid levels, illness and mortality for individuals at high"/>
  <result pre="shown the presence of mitochondrial-induced myopathies brought on through reduced" exact="respiratory" post="enzyme activity, calcium leakage and ROS-induced oxidative stress in"/>
  <result pre="reported incidence varies between 5% and 30% with the milder" exact="disease" post="being more common than the very rare rhabdomyolysis reported"/>
  <result pre="the milder disease being more common than the very rare" exact="rhabdomyolysis" post="reported at 1 in 10 000 patients. Chemotherapeutic agents are"/>
  <result pre="must be potent in order to combat the highly resistant" exact="cancer" post="cells; however, many chemotherapy agents cause the generation of"/>
  <result pre="regulate many cellular pathways including wound healing [44], survival under" exact="hypoxia" post="[45], intracellular pH homeostasis [46], innate immunity [47] and"/>
  <result pre="pH homeostasis [46], innate immunity [47] and cell differentiation [48]." exact="Mitochondrial" post="off-target effects are also observed with anti-psychotic drugs. Anti-psychotic"/>
  <result pre="became the standard of care for psychiatric disorders such as" exact="schizophrenia" post="and mood disorders in the 1950s with the development"/>
  <result pre="standard of care for psychiatric disorders such as schizophrenia and" exact="mood disorders" post="in the 1950s with the development of chlorpromazine, the"/>
  <result pre="epileptic drug sodium valproate has well documented mitochondrial toxicity showing" exact="respiratory" post="dysfunction in vitro in HEPG2 cells [51] and in"/>
  <result pre="dysfunction has been associated with hepatotoxicity [52] and foetal anticonvulsant" exact="syndrome" post="[53]. Mitochondrial linked organ toxicities are the commonest reason"/>
  <result pre="been associated with hepatotoxicity [52] and foetal anticonvulsant syndrome [53]." exact="Mitochondrial" post="linked organ toxicities are the commonest reason for licensed"/>
  <result pre="gender, state of immunity, and number and severity of pathogenic" exact="infections" post="[55,56]. Mitochondria become larger, less numerous and less efficient"/>
  <result pre="in the decline of mitophagy in age-related pathologies such as" exact="Alzheimer's disease" post="and Parkinson's disease (PD) [57]. The result of this"/>
  <result pre="the decline of mitophagy in age-related pathologies such as Alzheimer's" exact="disease" post="and Parkinson's disease (PD) [57]. The result of this"/>
  <result pre="of mitophagy in age-related pathologies such as Alzheimer's disease and" exact="Parkinson's disease" post="(PD) [57]. The result of this decline is a"/>
  <result pre="mitophagy in age-related pathologies such as Alzheimer's disease and Parkinson's" exact="disease" post="(PD) [57]. The result of this decline is a"/>
  <result pre="to the accumulation of dysfunctional mitochondria [58]. Genetics also influences" exact="susceptibility to" post="mitochondrial and metabolic dysfunction. For example, the mtDNA genetic"/>
  <result pre="oxidative damage, altered antioxidant status and onset of type two" exact="diabetes" post="[59–61]. Furthermore, different mtDNA haplogroups have been increasingly associated"/>
  <result pre="Furthermore, different mtDNA haplogroups have been increasingly associated with individual" exact="susceptibility to" post="toxic side effects observed in some patients [62–66]. Haplogroups,"/>
  <result pre="function, it has since been shown that specific haplogroups increase" exact="susceptibility to" post="toxic side effects of drug use; for example, the"/>
  <result pre="T and the subhaplo group L02a are associated with NRTI-induced" exact="peripheral neuropathy" post="[64,65]. The accumulation of SNPs in mtDNA, combined with"/>
  <result pre="and the subhaplo group L02a are associated with NRTI-induced peripheral" exact="neuropathy" post="[64,65]. The accumulation of SNPs in mtDNA, combined with"/>
  <result pre="the development of idiosyncratic drug-induced adverse effects [63]. Opportunities in" exact="disease" post="treatment using mitochondrial drug-induced effects As suggested above, screening"/>
  <result pre="has revealed over the past decade a dependency of many" exact="cancer" post="types on mitochondrial function. These dependencies can be shown"/>
  <result pre="has proved efficacious in these studies. Potentially useful new therapeutic" exact="cancer" post="agents such as the common antibiotic doxycycline with only"/>
  <result pre="to the treatment of cancer. Recent research has demonstrated that" exact="cancer" post="cells have a strong reliance on mitochondrial function particularly"/>
  <result pre="strong reliance on mitochondrial function particularly in the area of" exact="metastatic" post="disease [69–72]. The new cancer drug ONC201 [73], which"/>
  <result pre="reliance on mitochondrial function particularly in the area of metastatic" exact="disease" post="[69–72]. The new cancer drug ONC201 [73], which has"/>
  <result pre="particularly in the area of metastatic disease [69–72]. The new" exact="cancer" post="drug ONC201 [73], which has demonstrated efficacy in cell"/>
  <result pre="culture and animal models, is currently being tested against multiple" exact="cancer" post="types and could have been discarded if put through"/>
  <result pre="ONC201 did not directly activate TRAIL in all of the" exact="cancer" post="cells in which it was effective but was impairing"/>
  <result pre="protease which is activated by ONC201 and results in increased" exact="cancer" post="cell killing [76,77]. There exists a range of disorders"/>
  <result pre="antioxidants to reduce oxidative stress-induced damage [78]. The treatments of" exact="epilepsy" post="and pyruvate dehydrogenase (PDH) deficiency are good examples of"/>
  <result pre="damage [78]. The treatments of epilepsy and pyruvate dehydrogenase (PDH)" exact="deficiency" post="are good examples of the therapeutic benefits of modulating"/>
  <result pre="2 where two drugs bithionol and meclizine are added to" exact="Ewings sarcoma" post="cancer cell lines. This is an effect we observed"/>
  <result pre="where two drugs bithionol and meclizine are added to Ewings" exact="sarcoma" post="cancer cell lines. This is an effect we observed"/>
  <result pre="two drugs bithionol and meclizine are added to Ewings sarcoma" exact="cancer" post="cell lines. This is an effect we observed with"/>
  <result pre="condition tested, bithionol and meclizine at higher doses inhibit oxygen" exact="consumption" post="(i.e. little change in fluorescence lifetime over time). However,"/>
  <result pre="effects against PD and Huntingdon's models [83–85]. Figure 2. Oxygen" exact="consumption" post="of Ewing sarcoma in the presence of Bithionol or"/>
  <result pre="PD and Huntingdon's models [83–85]. Figure 2. Oxygen consumption of" exact="Ewing sarcoma" post="in the presence of Bithionol or Meclizine. Ewing sarcoma"/>
  <result pre="and Huntingdon's models [83–85]. Figure 2. Oxygen consumption of Ewing" exact="sarcoma" post="in the presence of Bithionol or Meclizine. Ewing sarcoma"/>
  <result pre="of Ewing sarcoma in the presence of Bithionol or Meclizine." exact="Ewing sarcoma" post="cell lines TC71 and A673 were seeded at 50k"/>
  <result pre="Ewing sarcoma in the presence of Bithionol or Meclizine. Ewing" exact="sarcoma" post="cell lines TC71 and A673 were seeded at 50k"/>
  <result pre="fluorescent lifetime levels in microseconds with increases, indicating higher oxygen" exact="consumption" post="(lower media levels). Horizontal axis indicates time in hours."/>
  <result pre="consumption (lower media levels). Horizontal axis indicates time in hours." exact="Mitochondrial" post="targeting to treat cancer In 2018, 17 million new"/>
  <result pre="Horizontal axis indicates time in hours. Mitochondrial targeting to treat" exact="cancer" post="In 2018, 17 million new cases of cancer were"/>
  <result pre="to treat cancer In 2018, 17 million new cases of" exact="cancer" post="were reported worldwide with 9.6 million deaths from the"/>
  <result pre="cancer were reported worldwide with 9.6 million deaths from the" exact="disease" post="[86]. Targeting malignancy and therapy resistance are the major"/>
  <result pre="Warburg was the first to suggest mitochondrial involvement in the" exact="disease" post="upon the observation that malignant cells have elevated uptake"/>
  <result pre="suggest mitochondrial involvement in the disease upon the observation that" exact="malignant" post="cells have elevated uptake of glucose, which undergoes fermentation"/>
  <result pre="not be the case, as functional mitochondria are essential for" exact="malignant" post="cell survival and oncogenesis [89]. This was highlighted by"/>
  <result pre="highlighted by reduced tumour growth and progression in mice when" exact="cancer" post="cells are made mtDNA deficient (ρ0) or when the"/>
  <result pre="mtDNA depletion [90]. Other data suggest that mtDNA mutations in" exact="cancer" post="are not linked to the development or spread and"/>
  <result pre="are not linked to the development or spread and that" exact="cancer" post="cells require the presence of active mitochondria to survive"/>
  <result pre="require the presence of active mitochondria to survive [91]. Targeting" exact="cancer" post="mitochondrial function is an exciting area with new drugs"/>
  <result pre="clinical trials across a wide range of tumour types [92–94]." exact="Mitochondrial" post="targeted drugs are presently being explored in combination with"/>
  <result pre="future. An increasing number of studies addressing the phenomenon of" exact="cancer" post="cell and metabolic-reprogramming conclude the essential nature of the"/>
  <result pre="microenvironment [100]. These bioenergetic adaptations depend greatly on mitochondrial function." exact="Complex" post="I's role in the glycolytic switch is one example"/>
  <result pre="decreases drug resistance and has activity in vivo against vemurafenib-resistant" exact="melanoma" post="[103]. Therefore, combinatorial treatments utilizing both OXPHOS and glycolytic"/>
  <result pre="OXPHOS and glycolytic inhibitors provide exciting new therapeutic opportunities [70]." exact="Mitochondrial" post="reprogramming in tumour progression extends beyond changes in mitochondrial"/>
  <result pre="mitochondrial bioenergetics. Tumour metastasis, a process implicated in 90% of" exact="cancer" post="deaths, is also dictated by changes in mitochondrial function"/>
  <result pre="of myc-driven tumour progression, where subcellular mitochondrial trafficking to the" exact="cortical" post="cytoskeleton is vital for tumour cell invasion and metastasis."/>
  <result pre="in the expression of OXPHOS genes and bioenergetics pathways [105]." exact="Mitochondrial" post="trafficking and redistribution is a vital and standard process"/>
  <result pre="same protein network is exploited by tumour cells to propel" exact="metastasis" post="[107]. The importance of mitochondrial trafficking in myc-driven tumours"/>
  <result pre="propel metastasis [107]. The importance of mitochondrial trafficking in myc-driven" exact="tumours" post="is further highlighted by the up-regulation of RHOT2, a"/>
  <result pre="is further highlighted by the up-regulation of RHOT2, a mitochondrial" exact="atypical" post="GTPase [107], and the down-regulation of syntaphilin (SNPH), an"/>
  <result pre="may have therapeutic benefit. Oxidative stress is a hallmark of" exact="cancer" post="cells as elevated ROS activates signalling pathways such as"/>
  <result pre="allow cells to cope with excessive ROS production in both" exact="malignant" post="and healthy cells [96]. Elevated ROS in cancer cells"/>
  <result pre="excessive ROS production in both malignant and healthy cells [96]." exact="Elevated" post="ROS in cancer cells is what differentiates malignant cells"/>
  <result pre="in both malignant and healthy cells [96]. Elevated ROS in" exact="cancer" post="cells is what differentiates malignant cells from healthy cells."/>
  <result pre="cells [96]. Elevated ROS in cancer cells is what differentiates" exact="malignant" post="cells from healthy cells. Thus, it is thought that"/>
  <result pre="it is thought that the inhibition of antioxidant systems in" exact="cancer" post="cells would cause an overload of ROS-induced damage leading"/>
  <result pre="cause an overload of ROS-induced damage leading to apoptosis in" exact="cancer" post="cells only. NSC130362, a small molecule glutathione inhibitor, is"/>
  <result pre="treatment developed to test this hypothesis. NSC130362 suppressed growth of" exact="cancer" post="cell lines and hindered tumour growth in vivo, but"/>
  <result pre="growth in vivo, but did not affect the viability of" exact="primary" post="human hepatocytes [110]. Furthermore, the molecule sensitized ex vivo"/>
  <result pre="primary human hepatocytes [110]. Furthermore, the molecule sensitized ex vivo" exact="leukaemia" post="cells to other anticancer drugs and potentiated their cytotoxic"/>
  <result pre="cause the accumulation of ROS beyond the antioxidant capacity of" exact="malignant" post="cells and result in apoptosis [111–113]. These drugs will"/>
  <result pre="will induce oxidative stress in healthy cells also; however, the" exact="malignant" post="cells already have elevated ROS such that the additional"/>
  <result pre="transcription, also play a crucial role in the tumorigenic process." exact="Mitochondrial" post="topoisomerase IB (TOP1MT) is a nuclear encoded, exclusively mitochondrial"/>
  <result pre="Mitochondrial topoisomerase IB (TOP1MT) is a nuclear encoded, exclusively mitochondrial" exact="localized" post="enzyme which is found overexpressed in some tumour types."/>
  <result pre="some tumour types. Baechler et al. [115] showed that HCT116" exact="colon cancer" post="cells had decreased tumour growth and cell proliferation in"/>
  <result pre="tumour types. Baechler et al. [115] showed that HCT116 colon" exact="cancer" post="cells had decreased tumour growth and cell proliferation in"/>
  <result pre="providing further proof of the importance of mitochondrial function in" exact="cancer" post="progression. In summary, many mitochondrial-specific, drug-induced adverse effects have"/>
  <result pre="mitochondrial derived dsRNA can induce antiviral signalling by triggering a" exact="type I" post="interferon response. In both the innate and adaptive immune"/>
  <result pre="responses through a variety of different mechanisms (Figure 3). The" exact="cytosolic" post="release of mtDNA can exert potent immunostimulatory effects. Mitochondrial"/>
  <result pre="The cytosolic release of mtDNA can exert potent immunostimulatory effects." exact="Mitochondrial" post="dysfunction or MOMP caused by pathogenic infection or toxic"/>
  <result pre="potent immunostimulatory effects. Mitochondrial dysfunction or MOMP caused by pathogenic" exact="infection" post="or toxic drugs can result in the release of"/>
  <result pre="[108] to activate immune responses. The predominant immunomodulatory action of" exact="cytosolic" post="mtDNA is through the activation of the STING pathway,"/>
  <result pre="the STING pathway, a critical antiviral regulatory system activated by" exact="viral" post="dsDNA during infection [118]. During an infection, viral pathogens"/>
  <result pre="a critical antiviral regulatory system activated by viral dsDNA during" exact="infection" post="[118]. During an infection, viral pathogens can cause mitochondrial"/>
  <result pre="activated by viral dsDNA during infection [118]. During an infection," exact="viral" post="pathogens can cause mitochondrial dysfunction within infected cells. This"/>
  <result pre="cause mitochondrial dysfunction within infected cells. This is achieved by" exact="viral" post="interference with mitochondrial signalling pathways and dynamics to favour"/>
  <result pre="viral interference with mitochondrial signalling pathways and dynamics to favour" exact="viral" post="proliferation and commonly occurs through the inhibition of apoptosis"/>
  <result pre="B cells (NFκB) transcription factors that control the expression of" exact="type I" post="interferons (IFN-I) and interferon-stimulated genes, which directly restrict viral"/>
  <result pre="type I interferons (IFN-I) and interferon-stimulated genes, which directly restrict" exact="viral" post="replication [16,57,121]. Drugs which induce mtDNA release or enhance"/>
  <result pre="the innate immune system or for increasing the efficiency of" exact="viral" post="clearance. mtDNA also contains a regulatory D-loop which allows"/>
  <result pre="responses. Figure 3. Cellular signalling pathways in response to pathogenic" exact="viral infection" post="or mtDNA release. Antiviral pathways can be stimulated by"/>
  <result pre="Figure 3. Cellular signalling pathways in response to pathogenic viral" exact="infection" post="or mtDNA release. Antiviral pathways can be stimulated by"/>
  <result pre="Induction of mild-to-moderate mitochondrial dysfunction through drug therapy could increase" exact="cytosolic" post="mtDNA and ROS production from impaired ETC function. These"/>
  <result pre="causing increased inflammatory responses and potentially more efficient pathogen and" exact="infection" post="clearance. However, care must be taken if using drug"/>
  <result pre="mtDNA release/sensing could be beneficial not only in clearing both" exact="viral" post="and bacterial infections, but also be effective tools in"/>
  <result pre="could be beneficial not only in clearing both viral and" exact="bacterial infections," post="but also be effective tools in engaging the immune"/>
  <result pre="be effective tools in engaging the immune system to destroy" exact="cancer" post="cells. Indeed, several drugs that increase STING activation are"/>
  <result pre="activation are being developed or are in clinical trials for" exact="cancer" post="therapy. These drugs perhaps may be paired with other"/>
  <result pre="through mtDNA depletion, increased ROS production and uncoupled OXPHOS [26,129,130]." exact="Mitochondrial" post="dysfunction results from off-target effects from these drugs rather"/>
  <result pre="the treatment of a variety of diseases such as cancer," exact="diabetes" post="and chronic viral infection. This can be achieved through"/>
  <result pre="of a variety of diseases such as cancer, diabetes and" exact="chronic" post="viral infection. This can be achieved through alterations in"/>
  <result pre="a variety of diseases such as cancer, diabetes and chronic" exact="viral infection." post="This can be achieved through alterations in mtDNA biogenesis,"/>
  <result pre="important field for the development of new therapeutic agents with" exact="lower" post="toxicity, as this is vital for patient safety and"/>
  <result pre="effects of current drugs is just as vital. Advancements in" exact="disease" post="treatment in the last century have left few new"/>
  <result pre="a main mode of action to treat diseases such as" exact="type 2" post="diabetes and cancer, as well as up-regulating the immune"/>
  <result pre="mode of action to treat diseases such as type 2" exact="diabetes" post="and cancer, as well as up-regulating the immune system"/>
  <result pre="cancer, as well as up-regulating the immune system to clear" exact="infection" post="with promising success; however, considerable caution must be taken"/>
  <result pre="considerable caution must be taken when inducing mitochondrial dysfunction for" exact="disease" post="treatment because of the vital dependency normal cells have"/>
  <result pre="role and function of mitochondria in both health and the" exact="disease" post="states in order to better take advantage of opportunities"/>
  <result pre="Abbreviations ATP adenosine triphosphate ETC electron transport chain HIV human" exact="immunodeficiency" post="virus IFN-I type I interferons MOMP mitochondrial outer membrane"/>
  <result pre="triphosphate ETC electron transport chain HIV human immunodeficiency virus IFN-I" exact="type I" post="interferons MOMP mitochondrial outer membrane permeabilization mtDNA mitochondrial DNA"/>
  <result pre="ROS NRTIs nucleoside reverse transcriptase inhibitors OXPHOS oxidative phosphorylation PD" exact="Parkinson's disease" post="PDH pyruvate dehydrogenase PRRs pattern recognition receptors RNA ribonucleic"/>
  <result pre="NRTIs nucleoside reverse transcriptase inhibitors OXPHOS oxidative phosphorylation PD Parkinson's" exact="disease" post="PDH pyruvate dehydrogenase PRRs pattern recognition receptors RNA ribonucleic"/>
  <result pre="exome data and its correlation with mitochondrial transcription, mass and" exact="respiratory" post="activity. Mitochondrion20, 13–2110.1016/j.mito.2014.10.00525446395 4BrinkmanK., ter HofstedeH., BurgerD., SmeitinkJ. and"/>
  <result pre="Transporting mitochondria in neurons. F1000Research5, 173510.12688/f1000research.7864.1 10ShengZ.H. and CaiQ. (2012)" exact="Mitochondrial" post="transport in neurons: impact on synaptic homeostasis and neurodegeneration."/>
  <result pre="and neurodegeneration. Nat. Rev. Neurosci.13, 77–9310.1038/nrn315622218207 11MagranéJ. and ManfrediG. (2009)" exact="Mitochondrial" post="function, morphology, and axonal transport in amyotrophic lateral sclerosis."/>
  <result pre="Neurosci.13, 77–9310.1038/nrn315622218207 11MagranéJ. and ManfrediG. (2009) Mitochondrial function, morphology, and" exact="axonal" post="transport in amyotrophic lateral sclerosis. Antioxid. Redox. Signal.11, 1615–162610.1089/ars.2009.260419344253"/>
  <result pre="and ManfrediG. (2009) Mitochondrial function, morphology, and axonal transport in" exact="amyotrophic lateral sclerosis." post="Antioxid. Redox. Signal.11, 1615–162610.1089/ars.2009.260419344253 12ReddyP.H. and ShirendebU.P. (2012) Mutant"/>
  <result pre="ManfrediG. (2009) Mitochondrial function, morphology, and axonal transport in amyotrophic" exact="lateral sclerosis." post="Antioxid. Redox. Signal.11, 1615–162610.1089/ars.2009.260419344253 12ReddyP.H. and ShirendebU.P. (2012) Mutant"/>
  <result pre="12ReddyP.H. and ShirendebU.P. (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective" exact="axonal" post="transport of mitochondria, and selective synaptic degeneration in Huntington's"/>
  <result pre="defective axonal transport of mitochondria, and selective synaptic degeneration in" exact="Huntington's disease." post="Biochim. Biophys. Acta1822, 101–11010.1016/j.bbadis.2011.10.01622080977 13LemastersJ., TheruvathT., ZhongZ. and NieminenA."/>
  <result pre="Biochim. Biophys. Acta1822, 101–11010.1016/j.bbadis.2011.10.01622080977 13LemastersJ., TheruvathT., ZhongZ. and NieminenA. (2009)" exact="Mitochondrial" post="calcium and the permeability transition in cell death. Biochim."/>
  <result pre="Cold Spring Harb. Perspect. Biol.5, a01131210.1101/cshperspect.a01131223906713 16WestA.P. and ShadelG. (2017)" exact="Mitochondrial" post="DNA in innate immune responses and inflammatory pathology. Nat."/>
  <result pre="LewinA. and AshJ. (2018) Mitochondria: potential targets for protection in" exact="age-related macular degeneration." post="Adv. Exp. Med. Biol.1074, 11–1710.1007/978-3-319-75402-4_229721922 23GuanR., ZouW., DaiX., YuX.,"/>
  <result pre="and AshJ. (2018) Mitochondria: potential targets for protection in age-related" exact="macular degeneration." post="Adv. Exp. Med. Biol.1074, 11–1710.1007/978-3-319-75402-4_229721922 23GuanR., ZouW., DaiX., YuX.,"/>
  <result pre="87 10.1186/s12929-018-0487-4 24DombiE., MortiboysH. and PoultonJ. (2019) Modulating mitophagy in" exact="mitochondrial disease." post="Curr. Med. Chem.25, 5597–561210.2174/0929867324666170616101741 25BerdisA. (2018) DNA polymerases as"/>
  <result pre="(2018) DNA polymerases as therapeutic targets. Biochemistry47, 8253–826010.1021/bi801179f 26WallaceK. (2008)" exact="Mitochondrial" post="off targets of drug therapy. Trends Pharmacol. Sci.29, 361–36610.1016/j.tips.2008.04.00118501972"/>
  <result pre="AkagiL. and MontanerJ.S.G. (2004) Adverse effects of antiretroviral therapy for" exact="HIV infection." post="CMAJ170, 229–23814734438 28LeeH., HanesJ. and JohnsonK. (2003) Toxicity of"/>
  <result pre="U.S.F.A.D. Administration (2019) Antiretroviral drugs used in the treatment of" exact="HIV infection," post="https://www.fda.gov/patients/hiv-treatment/antiretroviral-drugs-used-treatment-hiv-infection[cited 18 June 2019]. 31QianY. and GuanM.X. (2009) Interaction"/>
  <result pre="deafness-associated mutation. Antimicrob. Agents Chemother.53, 4612–461810.1128/AAC.00965-0819687236 32collab: NIDCD (2019) Age-related" exact="hearing loss" post=", https://www.nidcd.nih.gov/health/age-related-hearing-loss[cited 4 July 2019]. 33GolombB.A. and EvansM.A. (2018)"/>
  <result pre="of action. Pharmacol. Ther.175, 1–1610.1016/j.pharmthera.2017.02.029 35RamachandranR. and WierzbickiA.S. (2017) Statins," exact="muscle" post="disease and mitochondria. J. Clin. Med.6, 7510.3390/jcm6080075 36NicolsonG. and"/>
  <result pre="action. Pharmacol. Ther.175, 1–1610.1016/j.pharmthera.2017.02.029 35RamachandranR. and WierzbickiA.S. (2017) Statins, muscle" exact="disease" post="and mitochondria. J. Clin. Med.6, 7510.3390/jcm6080075 36NicolsonG. and ConklinK."/>
  <result pre="mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of" exact="metastatic" post="disease by molecular replacement therapy. Clin. Exp. Metastasis25, 161–16910.1007/s10585-007-9129-z18058028"/>
  <result pre="dysfunction, fatigue and the adverse effects of chemotherapy of metastatic" exact="disease" post="by molecular replacement therapy. Clin. Exp. Metastasis25, 161–16910.1007/s10585-007-9129-z18058028 37FinkelT."/>
  <result pre="increasing oxidative stress. Cell Metab.6, 280–29310.1016/j.cmet.2007.08.01117908557 41DianoS. and HorvathT.L. (2012)" exact="Mitochondrial" post="uncoupling protein 2 (UCP2) in glucose and lipid metabolism."/>
  <result pre="Immunol.11, 389–40210.1038/nri297521597473 48HamanakaR.B., GlasauerA., HooverP., YangS., BlattH., MullenA.R.et al. (2013)" exact="Mitochondrial" post="reactive oxygen species promote epidermal differentiation and hair follicle"/>
  <result pre="Inherit. Metab. Dis.20, 397–40010.1023/A:10053985162089266365 53KulkarniM., ZaheeruddinM., ShenoyN. and VaniH. (2006)" exact="Fetal valproate syndrome." post="Indian J. Pediatr.73 54WillY. and DykensJ. (2014) Mitochondrial toxicity"/>
  <result pre="Fetal valproate syndrome. Indian J. Pediatr.73 54WillY. and DykensJ. (2014)" exact="Mitochondrial" post="toxicity assessment in industry — a decade of technology"/>
  <result pre="medications. J. Med. Toxicol.10, 26–3910.1007/s13181-013-0325-8 57FangC., WeiX. and WeiY. (2015)" exact="Mitochondrial" post="DNA in the regulation of innate immune responses. Protein"/>
  <result pre="(2015) Mitochondrial DNA in the regulation of innate immune responses." exact="Protein" post="Cell7, 11–1610.1007/s13238-015-0222-9 58SrivastavaS. (2017) The mitochondrial basis of aging"/>
  <result pre="Genes8, 39810.3390/genes8120398 59LinT., ChenS., WangP., WeiY., LeeC., ChenT.et al. (2005)" exact="Increased" post="oxidative damage with altered antioxidative status in type 2"/>
  <result pre="al. (2005) Increased oxidative damage with altered antioxidative status in" exact="type 2" post="diabetic patients harboring the 16189T to C variant of"/>
  <result pre="Sci.1042, 64–6910.1196/annals.1338.00715965046 60PintiM., FinkG., HathawayQ., DurrA., KunovacA. and HollanderJ. (2019)" exact="Mitochondrial" post="dysfunction in type 2 diabetes mellitus: an organ-based analysis."/>
  <result pre="FinkG., HathawayQ., DurrA., KunovacA. and HollanderJ. (2019) Mitochondrial dysfunction in" exact="type 2" post="diabetes mellitus: an organ-based analysis. Am. J. Physiol.-Endocrinol. Metab.316,"/>
  <result pre="DurrA., KunovacA. and HollanderJ. (2019) Mitochondrial dysfunction in type 2" exact="diabetes" post="mellitus: an organ-based analysis. Am. J. Physiol.-Endocrinol. Metab.316, E268–E28510.1152/ajpendo.00314.201830601700"/>
  <result pre="(2016) Role of mitochondrial DNA variation in the pathogenesis of" exact="diabetes mellitus." post="Front. Biosci.21, 1151–116710.2741/4447 62Pacheu-GrauD., Gomez-DuranA., IglesiasE., Lopez-GallardoE., MontoyaJ. and"/>
  <result pre="Biosci.21, 1151–116710.2741/4447 62Pacheu-GrauD., Gomez-DuranA., IglesiasE., Lopez-GallardoE., MontoyaJ. and Ruiz-PesiniE. (2012)" exact="Mitochondrial" post="antibiograms in personalized medicine. Hum. Mol. Genet.22, 1132–113910.1093/hmg/dds51723223015 63PereiraC.,"/>
  <result pre="Hum. Mol. Genet.22, 1132–113910.1093/hmg/dds51723223015 63PereiraC., OliveiraP., WillY. and NadanacivaS. (2012)" exact="Mitochondrial" post="bioenergetics and drug-induced toxicity in a panel of mouse"/>
  <result pre="The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated" exact="peripheral neuropathy." post="Pharmacogenomics J.8, 71–7710.1038/sj.tpj.650047017684475 65KampiraE., KumwendaJ., van OosterhoutJ. and DandaraC."/>
  <result pre="Pharmacogenomics J.8, 71–7710.1038/sj.tpj.650047017684475 65KampiraE., KumwendaJ., van OosterhoutJ. and DandaraC. (2013)" exact="Mitochondrial" post="DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral"/>
  <result pre="and DandaraC. (2013) Mitochondrial DNA subhaplogroups L0a2 and L2a modify" exact="susceptibility to" post="peripheral neuropathy in Malawian adults on stavudine containing highly"/>
  <result pre="(2013) Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to" exact="peripheral neuropathy" post="in Malawian adults on stavudine containing highly active antiretroviral"/>
  <result pre="Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral" exact="neuropathy" post="in Malawian adults on stavudine containing highly active antiretroviral"/>
  <result pre="the mitochondrial toxicity of linezolid in blood cells and skin" exact="nerve" post="fibers. Antimicrob. Agents Chemother.61, e00542–e0051710.1128/AAC.00542-1728674062 67AhlerE., SullivanW., CassA., BraasD.,"/>
  <result pre="FujitaT., YamadaH., ChiaoP.J.et al. (2009) Doxycycline induces apoptosis in PANC-1" exact="pancreatic cancer" post="cells. Anticancer Res.29, 3995–400319846942 69PotterM., NewportE. and MortenK. (2016)"/>
  <result pre="YamadaH., ChiaoP.J.et al. (2009) Doxycycline induces apoptosis in PANC-1 pancreatic" exact="cancer" post="cells. Anticancer Res.29, 3995–400319846942 69PotterM., NewportE. and MortenK. (2016)"/>
  <result pre="TanJ., WongA., ClementM., KongL.et al. (2018) Metabolic reprogramming of oncogene-addicted" exact="cancer" post="cells to OXPHOS as a mechanism of drug resistance."/>
  <result pre="Biol.101076 PMID:30642723 71TanA.S., BatyJ.W., DongL.F., Bezawork-GeletaA., EndayaB., GoodwinJ.et al. (2015)" exact="Mitochondrial" post="genome acquisition restores respiratory function and tumorigenic potential of"/>
  <result pre="DongL.F., Bezawork-GeletaA., EndayaB., GoodwinJ.et al. (2015) Mitochondrial genome acquisition restores" exact="respiratory" post="function and tumorigenic potential of cancer cells without mitochondrial"/>
  <result pre="Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of" exact="cancer" post="cells without mitochondrial DNA. Cell Metab.6, 81–9410.1016/j.cmet.2014.12.003 72KelleyL.C., ChiQ.,"/>
  <result pre="CáceresR., HastieE., SchindlerA.J., JiangY.et al. (2019) Adaptive F-actin polymerization and" exact="localized" post="ATP production drive basement membrane invasion in the absence"/>
  <result pre="and localized ATP production drive basement membrane invasion in the" exact="absence of" post="MMPs. Dev. Cell48, 313–32810.1016/j.devcel.2018.12.01830686527 73collab: OncoceuticsONC201 clinical trials 2019,"/>
  <result pre="75GreerY., Porat-ShliomN., NagashimaK., StueltenC., CrooksD., KopardeV.et al. (2018) ONC201 kills" exact="breast cancer" post="cells in vitro by targeting mitochondria. Oncotarget910.18632/oncotarget.24862 76GravesP., Aponte-CollazoL.,"/>
  <result pre="Porat-ShliomN., NagashimaK., StueltenC., CrooksD., KopardeV.et al. (2018) ONC201 kills breast" exact="cancer" post="cells in vitro by targeting mitochondria. Oncotarget910.18632/oncotarget.24862 76GravesP., Aponte-CollazoL.,"/>
  <result pre="mitochondria. Oncotarget910.18632/oncotarget.24862 76GravesP., Aponte-CollazoL., FennellE., GravesA., HaleA., DichevaN.et al. (2019)" exact="Mitochondrial" post="protease ClpP is a target for the anticancer compounds"/>
  <result pre="Biol.14, 1020–102910.1021/acschembio.9b0022231021596 77IshizawaJ., ZarabiS., DavisR., HalgasO., NiiT., JitkovaY.et al. (2019)" exact="Mitochondrial" post="ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell35,"/>
  <result pre="HalgasO., NiiT., JitkovaY.et al. (2019) Mitochondrial ClpP-mediated proteolysis induces selective" exact="cancer" post="cell lethality. Cancer Cell35, 721–73710.1016/j.ccell.2019.03.01431056398 78RibeiroM., Castro e SantosA."/>
  <result pre="al. (2019) Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality." exact="Cancer" post="Cell35, 721–73710.1016/j.ccell.2019.03.01431056398 78RibeiroM., Castro e SantosA. and CustódioJ., (2015)"/>
  <result pre="Cancer Cell35, 721–73710.1016/j.ccell.2019.03.01431056398 78RibeiroM., Castro e SantosA. and CustódioJ., (2015)" exact="Mitochondrial" post="dysfunction on the toxic effects of anticancer agents —"/>
  <result pre="ZhangF., ZhangY.et al. (2018) Ketogenic diet for treatment of intractable" exact="epilepsy" post="in adults: a meta-analysis of observational studies. Epilepsia Open3,"/>
  <result pre="ArteroA., TarínJ.J. and CanoA. (2015) The impact of moderate wine" exact="consumption" post="on health. Maturitas80, 3–1310.1016/j.maturitas.2014.09.00725449821 83GohilV., OffnerN., WalkerJ., ShethS., FossaleE.,"/>
  <result pre="FossaleE., GusellaJ.et al. (2010) Meclizine is neuroprotective in models of" exact="Huntington's disease." post="Hum. Mol. Genet.20, 294–30010.1093/hmg/ddq46420977989 84GohilV., ZhuL., BakerC., CracanV., YaseenA.,"/>
  <result pre="al. (2013) Meclizine inhibits mitochondrial respiration through direct targeting of" exact="cytosolic" post="phosphoethanolamine metabolism. J. Biol. Chem.288, 35387–3539510.1074/jbc.M113.48923724142790 85HongC., ChauK. and"/>
  <result pre="ChauK. and SchapiraA. (2016) Meclizine-induced enhanced glycolysis is neuroprotective in" exact="Parkinson" post="disease cell models. Sci. Rep.6, 25344 PMID:27145922 86Cancer Research"/>
  <result pre="and SchapiraA. (2016) Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson" exact="disease" post="cell models. Sci. Rep.6, 25344 PMID:27145922 86Cancer Research UK."/>
  <result pre="models. Sci. Rep.6, 25344 PMID:27145922 86Cancer Research UK. (2019) Worldwide" exact="cancer" post="statistics, https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer[cited 13 March 2019]. 87WarburgO. (1927) The metabolism"/>
  <result pre="Physiol.8, 519–53010.1085/jgp.8.6.51919872213 88MalviyaG. and NayakT. (2014) PET imaging to monitor" exact="cancer" post="therapy. Curr. Pharm. Biotechnol.14, 669–68210.2174/1389201014666131226104750 89PustylnikovS., CostabileF., BeghiS. and"/>
  <result pre="BandiM., BristowC.et al. (2018) An inhibitor of oxidative phosphorylation exploits" exact="cancer" post="vulnerability. Nat. Med.24, 1036–104610.1038/s41591-018-0052-429892070 94ZhangL., YaoY., ZhangS., LiuY., GuoH.,"/>
  <result pre="Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for" exact="mantle cell lymphoma." post="Sci. Transl. Med.11, eaau116710.1126/scitranslmed.aau116731068440 95Liu YZ.X., ZhouM., NanX., ChenX."/>
  <result pre="CheltsovA., NilsenA., BonifaceC., ForquerI., KorkolaJ.et al. (2019) Targeting mitochondria in" exact="cancer" post="therapy could provide a basis for the selective anti-cancer"/>
  <result pre="tumors. Redox Biol.10107310.1016/j.redox.2018.101073 100PorporatoP., FilighedduN., PedroJ., KroemerG. and GalluzziL. (2017)" exact="Mitochondrial" post="metabolism and cancer. Cell Res.28, 265–28010.1038/cr.2017.15529219147 101ChavezA., MirandaL., PichiuleP."/>
  <result pre="Sci.1147, 312–32010.1196/annals.1427.02119076453 102CalabreseC., IommariniL., KurelacI., CalvarusoM., CapristoM., LolliniP.et al. (2013)" exact="Respiratory" post="complex I is essential to induce a Warburg profile"/>
  <result pre="I is essential to induce a Warburg profile in mitochondria-defective" exact="tumor" post="cells. Cancer Metab.1, 1110.1186/2049-3002-1-1124280190 103BonnerM., KarlssonI., RodolfoM., ArnoldR., VerganiE."/>
  <result pre="essential to induce a Warburg profile in mitochondria-defective tumor cells." exact="Cancer" post="Metab.1, 1110.1186/2049-3002-1-1124280190 103BonnerM., KarlssonI., RodolfoM., ArnoldR., VerganiE. and ArbiserJ."/>
  <result pre="ArbiserJ. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant" exact="melanoma" post="in vivo. Oncotarget710.18632/oncotarget.7289 104AltieriD.C. (2019) Mitochondrial dynamics and metastasis."/>
  <result pre="demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget710.18632/oncotarget.7289 104AltieriD.C. (2019)" exact="Mitochondrial" post="dynamics and metastasis. Cell. Mol. Life Sci.76, 827–83510.1007/s00018-018-2961-230415375 105AgarwalE.,"/>
  <result pre="al. (2019) Myc regulation of a mitochondrial trafﬁcking network mediates" exact="tumor" post="cell invasion and metastasis. Mol. Cell. Biol.39, e00109–e0011910.1128/MCB.00109-1931061095 106ShengZ."/>
  <result pre="cell invasion and metastasis. Mol. Cell. Biol.39, e00109–e0011910.1128/MCB.00109-1931061095 106ShengZ. (2014)" exact="Mitochondrial" post="trafficking and anchoring in neurons: new insight and implications."/>
  <result pre="1087–109810.1083/jcb.20131212324687278 107CainoM., SeoJ., AguinaldoA., WaitE., BryantK., KossenkovA.et al. (2016) A" exact="neuronal" post="network of mitochondrial dynamics regulates metastasis. Nat. Commun.7, 1373010.1038/ncomms1373027991488"/>
  <result pre="PLoS ONE10, e0129566 PMID:26075913 111WenS., ZhuD. and HuangP. (2013) Targeting" exact="cancer" post="cell mitochondria as a therapeutic approach. Future Med. Chem.5,"/>
  <result pre="mitochondrial membrane potential change and apoptosis induced by doxycycline in" exact="melanoma" post="cells. Br. J. Pharmacol.160, 1171–118410.1111/j.1476-5381.2010.00746.x20590610 114MohammadH., BarbashO. and CreasyC."/>
  <result pre="1171–118410.1111/j.1476-5381.2010.00746.x20590610 114MohammadH., BarbashO. and CreasyC. (2019) Targeting epigenetic modifications in" exact="cancer" post="therapy: erasing the roadmap to cancer. Nat. Med.25, 403–41810.1038/s41591-019-0376-830842676"/>
  <result pre="Sci.125, 807–81510.1242/jcs.09923422448037 117DhirA., DhirS., BorowskiL.S., JimenezL., TeitellM., RötigA.et al. (2018)" exact="Mitochondrial" post="double-stranded RNA triggers antiviral signalling in humans. Nature560, 238–24210.1038/s41586-018-0363-030046113"/>
  <result pre="Commun. Signal.13, 303–318 PMID:30719617 119KhanM., SyedG.H., KimS. and SiddiquiA. (2015)" exact="Mitochondrial" post="dynamics and viral infections: a close nexus. Biochim. Biophys."/>
  <result pre="PMID:30719617 119KhanM., SyedG.H., KimS. and SiddiquiA. (2015) Mitochondrial dynamics and" exact="viral" post="infections: a close nexus. Biochim. Biophys. Acta1853, 2822–283310.1016/j.bbamcr.2014.12.04025595529 120CôtéH.,"/>
  <result pre="Med.346, 811–82010.1056/NEJMoa01203511893792 121WestA., Khoury-HanoldW., StaronM., TalM., PinedaC., LangS.et al. (2015)" exact="Mitochondrial" post="DNA stress primes the antiviral innate immune response. Nature520,"/>
  <result pre="Chem.290, 27425–2743710.1074/jbc.M115.66706326416893 128WiddringtonJ., Gomez-DuranA., SteynJ., PyleA., Ruchaud-SparaganoM., ScottJ.et al. (2017)" exact="Mitochondrial" post="DNA depletion induces innate immune dysfunction rescued by IFN-γ."/>
  <result pre="J. Allergy Clin. Immunol.140, 1461–146410.1016/j.jaci.2017.04.04828629747 129CantaA., PozziE. and CarozziV. (2015)" exact="Mitochondrial" post="dysfunction in chemotherapy-induced peripheral neuropathy. Toxics3, 198–22310.3390/toxics302019829056658 130LiY., CouchL.,"/>
  <result pre="1461–146410.1016/j.jaci.2017.04.04828629747 129CantaA., PozziE. and CarozziV. (2015) Mitochondrial dysfunction in chemotherapy-induced" exact="peripheral neuropathy." post="Toxics3, 198–22310.3390/toxics302019829056658 130LiY., CouchL., HiguchiM., FangJ. and GuoL. (2012)"/>
  <result pre="neuropathy. Toxics3, 198–22310.3390/toxics302019829056658 130LiY., CouchL., HiguchiM., FangJ. and GuoL. (2012)" exact="Mitochondrial" post="dysfunction induced by sertraline, an antidepressant agent. Toxicol. Sci.127,"/>
  <result pre="synthesis. Antimicrob. Agents Chemother.38, 2743–274910.1128/AAC.38.12.27437695256 133LewisW., DayB. and CopelandW. (2003)" exact="Mitochondrial" post="toxicity of NRTI antiviral drugs: an integrated cellular perspective."/>
  <result pre="Discov.2, 812–82210.1038/nrd120114526384 134LabergeR., AdlerD., DeMariaM., MechtoufN., TeachenorR., CardinG.et al. (2013)" exact="Mitochondrial" post="DNA damage induces apoptosis in senescent cells. Cell Death"/>
  <result pre="zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human" exact="muscle" post="cells. J. Neurol. Sci.149, 19–2510.1016/S0022-510X(97)05376-89168161 136LewisW., PapoianT., GonzalezB., LouieH.,"/>
  <result pre="Sci.149, 19–2510.1016/S0022-510X(97)05376-89168161 136LewisW., PapoianT., GonzalezB., LouieH., KellyD.P., PayneR.M.et al. (1991)" exact="Mitochondrial" post="ultrastructural and molecular changes induced by zidovudine in rat"/>
  <result pre="139ArnaudoE., ShanskeS., DiMauroS., SchonE., MoraesC., SchonE.et al. (1991) Depletion of" exact="muscle" post="mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet3377,"/>
  <result pre="1–24, Springer-Verlag, Berlin, Heidelberg 141BrinkmanK., SmeitinkJ., RomijnJ. and ReissP. (1999)" exact="Mitochondrial" post="toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key"/>
  <result pre="antiretroviral-therapy-related lipodystrophy. Lancet354, 1112–111510.1016/S0140-6736(99)06102-410509516 142LleonartM., GrodzickiR., GraiferD. and LyakhovichA. (2017)" exact="Mitochondrial" post="dysfunction and potential anticancer therapy. Med. Res. Rev.37, 1275–129810.1002/med.2145928682452"/>
  <result pre="Nucleic Acids Res.46, 9625–963610.1093/nar/gky79330169847 144LawrenceJ.W., ClaireD.C., WeissigV. and RoweT.C. (1996)" exact="Delayed" post="cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian"/>
  <result pre="cause a selective loss of mitochondrial DNA from mouse L1210" exact="leukemia" post="cells. J. Cell. Biochem.51, 165–17410.1002/jcb.2405102088440750 147WangD., LiuY., ZhangR., ZhangF.,"/>
  <result pre="mitochondrial hyper-function. Oncotarget7, 28286–2830027056883 148DasariS. and TchounwouP.B. (2014) Cisplatin in" exact="cancer" post="therapy: molecular mechanisms of action. Eur. J. Pharmacol.740, 364–37810.1016/j.ejphar.2014.07.02525058905"/>
  <result pre="mitochondrial oxidations. Biochem. Pharmacol.43, 2435–244210.1016/0006-2952(92)90324-C1610408 158SangkuhlK., KleinT. and AltmanR. (2009)" exact="Selective" post="serotonin reuptake inhibitors pathway. Pharmacogenet. Genomics19, 907–90910.1097/FPC.0b013e32833132cb19741567 159SouzaM., PolizelloA.,"/>
  <result pre="(2009) A comparative proteomics analysis of Rat mitochondria from the" exact="cerebral" post="cortex and hippocampus in response to antipsychotic medications. J."/>
 </snippets>
</snippetsTree>
